Classes
Publications
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy2012 | First Faculty of Medicine
- Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population2011 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Jistoty a nejistoty na křižovatkách současné medicíny2023 | First Faculty of Medicine
- Slibný perorální inhibitor PCSK9 ve vývoji2023 | First Faculty of Medicine
- Internista2023 | First Faculty of Medicine
- Vitamin B12 deficiency: a continent hidden from the eyes of diabetologists2023 | First Faculty of Medicine
- Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases +12022 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
Loading network view...